Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.

Area of Science:

• Biomedical Engineering
• Cancer Immunology
• Cell Therapy

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematological cancer treatment but faces challenges in solid tumors.
• The solid tumor microenvironment, particularly hypoxia, significantly impacts CAR-T cell function and efficacy.
• Current in vitro models lack the complexity to accurately study CAR-T cell-tumor interactions in a physiological oxygen gradient.

Purpose of the Study:

• To engineer a microdevice platform that mimics the in vivo solid tumor microenvironment with oxygen gradients.
• To evaluate the efficacy and infiltration of CAR-T cells within this engineered tumor model.
• To provide a scalable in vitro system for mechanistic studies of CAR-T cell biology in solid tumors.

Main Methods:

• Development of a microfluidic device featuring a 3D tumor section with controlled oxygen gradients.
• Integration of fluidic channels for CAR-T cell delivery and observation.
• Assessment of CAR-T cell cytotoxicity and infiltration within the heterogeneous oxygen landscape.

Main Results:

• The microdevice successfully recapitulates the oxygen heterogeneity found in solid tumors.
• The platform allows for detailed observation of CAR-T cell behavior and efficacy under varying oxygen levels.
• This model provides unprecedented in vitro scale for studying CAR-T cell-tumor interactions.

Conclusions:

• The engineered microdevice platform is a valuable tool for understanding CAR-T cell therapy limitations in solid tumors.
• This technology facilitates mechanistic studies of CAR-T cell function in hypoxic tumor microenvironments.
• The platform holds potential for improving CAR-T cell therapy strategies against solid cancers.